Firefly Neuroscience

Revenue is small and concentrated in early rollouts and projects. 2025 revenue was 1.142 million dollars and 1H26 revenue was 0.999 million dollars. Deferred revenue and leased equipment disclosures show some subscription visibility, but the base is modest.

Regulatory, payer and training variables add noise, and pharma services are inherently project‑based. We do not yet see tollbooth‑like predictability.